X

Trial Profile

Open-label, Safety and Efficacy Evaluation of FX-1006A in Patients With V122I or Wild-type Transthyretin (TTR) Amyloid Cardiomyopathy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafamidis meglumine (Primary)
Indications Cardiomyopathies; Heart failure
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Pfizer

Most Recent Events

16 Sep 2020 Status changed from active, no longer recruiting to completed.
12 Aug 2020 Planned End Date changed from 1 Dec 2021 to 31 Dec 2020.
12 Aug 2020 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com